Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: Degarelix vs goserelin plus bicalutamide

BJU International

Volumn 110, Issue 11, 2012, Pages 1721-1728

  Axcrona, Karol ^a   Aaltomaa, Sirpa ^b   Da Silva, Carlos Martins ^c   Özen, Haluk ^d   Damber, Jan Erik ^e   Tankó, László B ^f   Colli, Enrico ^f   Klarskov, Peter ^g  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d HACETTEPE UNIVERSITY   (Turkey)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f Ferring Pharmaceuticals AS   (Denmark)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

patients with prostate cancer; prostate volume reduction; short term androgen deprivation; urinary symptom management

Indexed keywords

BICALUTAMIDE; DEGARELIX; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ABNORMAL LABORATORY RESULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BENIGN PROSTATE HYPERPLASIA IMPACT INDEX; BLADDER CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HOT FLUSH; HUMAN; HYPERHIDROSIS; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TUMOR REGRESSION; URETER OBSTRUCTION; VITAL SIGN;

EID: 84870946305     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11107.x     Document Type: Article

References (32)

1. Labrie F, Bélanger A, Luu-The V, et al,. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005; 26: 361-79
2. Van Poppel H,. Evaluation of degarelix in the management of prostate cancer. Cancer Manag Res 2010; 2: 39-52
3. Sugiono M, Winkler MH, Okeke AA, Benney M, Gillatt DA,. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer-a pilot study. Prostate Cancer Prostatic Dis 2005; 8: 91-4
4. Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK, Degarelix Study Group. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008; 180: 1986-92
5. Hamilton W, Sharp D,. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract 2004; 54: 617-21
6. Guess HA,. Benign prostatic hyperplasia and prostate cancer. Epidemiol Rev 2001; 23: 152-8
7. Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE,. Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men. BJU Int 2004; 94: 327-31
8. Lehrer S, Stone NN, Droller MJ, Stock RG,. Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. Urol Oncol 2002; 7: 73-6
9. Stone NN, Marshall DT, Stone JJ, Cesaretti JA, Stock RG,. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? J Urol 2010; 183: 634-9
10. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ,. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46: 547-54
11. Roehrborn CG, Siami P, Barkin J, et al,. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-21; discussion 621
12. Barry MJ, Williford WO, Chang Y, et al,. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770-4
13. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK,. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care 1995; 33 (Suppl.): AS145-55
14. Gleave ME, Goldenberg SL, Chin JL, et al,. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 500-6; discussion 506-
15. Langenhuijsen JF, van Lin EN, Hoffmann AL, et al,. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol 2011; 29: 52-7
16. Ebara S, Manabe D, Kobayashi Y, et al,. The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer. Acta Med Okayama 2007; 61: 335-40
17. Sanghani MV, Schultz D, Tempany CM, et al,. Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology 2003; 62: 487-91
18. Blank KR, Whittington R, Arjomandy B, et al,. Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity. Cancer J Sci Am 1999; 5: 370-3
19. Kucway R, Vicini F, Huang R, Stromberg J, Gonzalez J, Martinez A,. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002; 167: 2443-7
20. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G,. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41
21. Mommsen S, Petersen L,. Transurethral catheter removal after bilateral orchiectomy for prostatic carcinoma associated with acute urinary retention. Scand J Urol Nephrol 1994; 28: 401-4
22. Klarskov L, Mommsen S, Klarskov P, Svoldgård N,. Endocrine treatment and LUTS in men with prostate cancer. Eur Urol 2006; 5 (Suppl. 5): 250. Abstract 909
23. Klarskov LL, Klarskov P, Mommsen S, Svolgaard N,. Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study. Scand J Urol Nephrol 2012; 46: 37-43
24. Oesterling JE,. LHRH agonists: a nonsurgical treatment of benign prostate hyperplasia. J Androl 1991; 12: 381-8
25. Russo A, Castiglione F, Salonia A, et al,. Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats. Eur Urol 2011; 59: 868-74
26. Bono AV, Salvadore M, Celato N,. Gonadotropin-releasing hormone receptors in prostate tissue. Anal Quant Cytol Histol 2002; 24: 221-7
27. Bahk JY, Kim MO, Park MS, et al,. Gonadotropin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation. Urol Int 2008; 80: 431-8
28. Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F, Bouloux PM,. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol 2005; 142: 103-10
29. Gandaglia G, Benigni F, La Croce G, et al,. Degarelix reduces urodynamic changes in a rat model for experimental detrusor overactivity and produces more efficient voiding. J Urol 2011; 185: e322
30. Rick FG, Schally AV, Block NL, et al,. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011; 71: 736-47
31. Siejka A, Schally AV, Block NL, Barabutis N,. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int 2010; 106: 1382-8
32. Giuliano F, Behr-Roussel D, Oger S, et al,. Ozarelix, an LHRH antagonist, exerts a direct relaxing effect on human prostate in vitro. J Urol 2009; 181: 693